1. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 56(25), e50–e103 (2010).
2. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115, 949–952 (2007).
3. PO Kwiterovich Jr. Lipid, apolipoprotein and lipoprotein metabolism: implications for the diagnosis and treatment of dyslipidemia. In: The Johns Hopkins Textbook of Dyslipidemia. Kwiterovich PO Jr (Ed.). Lippincott Williams and Wilkins, PA, USA, 1–21 (2009).
4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J. Intern. Med. 255(2), 188–205 (2004).
5. Sniderman AD, de Graaf J, Couture P. ApoB and the atherogenic apoB dyslipoproteinemias. In: The Johns Hopkins Textbook of Dyslipidemia. Kwiterovich PO Jr (Ed.). Lippincott Williams and Wilkins, PA, USA, 196–210 (2009).